Mursla Bio

.@Mursla announced that it has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator 2026 Programme, which will accelerate US commercial deployment of its FDA-designated liver cancer surveillance test, EvoLiver™. bit.ly/3MHrz2J

🎉 We are proud to announce that Mursla Bio is partnering with a leading global pharmaceutical company to advance its drug for metabolic liver disease. For more information, check out our press release here: lnkd.in/eQEGCfRv #PrecisionMedicine #MASH #Diagnostics #EVScience #BigPharma

When Nature Reviews Clinical Oncology (IF = 65) highlights your technology, it is a good sign🔬

✨ We are pleased that Mursla Bio’s core technology was recently featured on @RevvityInc (NYSE: RVTY) website, highlighting its unique precision diagnostic capabilities. The article discusses how Mursla’s approach to isolating organ-specific extracellular vesicles (EVs) from plasma helps overcome a critical challenge in EV and microRNA research. Notably: - In blood, almost all EVs originate from hematopoietic cells, drowning out signals from solid organs. - Following the enrichment for hepatocyte-derived EVs by Mursla's technology, small RNA-seq libraries revealed microRNA species tightly linked to liver biology and liver cancer that were invisible in bulk EVs. This is especially timely as microRNA biology was honored with the 2024 Nobel Prize in Medicine, underscoring its power as a key regulator of gene expression and as a relevant biomarker class. Revvity concludes that: - Organ-specific EVs deliver quality and biological resolution, unlike bulk EVs that only provide quantity. - They enable signals from defined tissues to emerge by analogy to single-cell sequencing, - This sets a new standard for reliable, multi-omic liquid biopsies with true biological interpretability. This capability underpins Mursla Bio’s AI Precision Medicine Platform, which contributed to the development of EvoLiver™, our first product for liver cancer surveillance. Check out the full post here: lnkd.in/eUS4C9_m More details on our NEXPLOR technology can be found in our recent preprint: lnkd.in/dXk54iyS

🧬 Mursla Bio was recently featured in a new article by @statnews , as a leading company that’s supporting the shift to extracellular vesicles (EVs) for early cancer detection. The article explains why many experts are looking beyond DNA-based blood tests. DNA is often present at low levels in early disease and breaks down easily, making detection difficult. EVs offer a compelling alternative. They are released by living cells and carry stable, information-rich cargo that reflects their tissue of origin, helping address critical gaps in test sensitivity and specificity. Our first product, EvoLiver™, designed for the early detection of liver cancer, is based on our breakthrough platform that isolates organ specific EVs from blood. Our platform can be extended to support broader applications in AI enabled precision medicine across oncology, cardiometabolic diseases, and neurology. Read the article here: statnews.com//2025/07/29/ea… [paywall]

Researchers are turning to a new approach for early cancer detection, making use of nanoscale biological structures called extracellular vesicles. trib.al/UPXmuUq

🧠 Introducing the Mursla Bio AI Precision Medicine Platform Mursla Bio is proud to announce the launch of its AI Precision Medicine Platform, a full-stack solution enabling organ-specific, multi-omic analysis from blood to advance precision diagnostics and patient stratification. Built on Mursla’s patented extracellular vesicle (EV) technology, the platform enables the isolation of tissue-specific EVs from just 2 milliliters of plasma. It delivers structured, biologically labelled multi-omic data from specific tissues that can drive biomarker discovery, predictive model development, and diagnostic translation. The platform has been validated in a newly released pre-print, developed in collaboration with @Evotec International and University College London (@ucl ). The study demonstrates what we believe to be the most comprehensive scientific validation to date of tissue-EV isolation from a specific human tissue (hepatocytes). Platform highlights: • Patented workflows for tissue-specific EV isolation and biomarker capture • Embedded AI pipelines for multi-omic biomarker discovery and predictive modelling • Proprietary assay formats compatible with standard laboratory instruments • Built for regulatory-grade, scalable diagnostic deployment The platform powers Mursla’s lead program, EvoLiver™, an early disease detection test for liver cancer surveillance in high-risk patients. EvoLiver has received FDA Breakthrough Device Designation. We are now opening access to the platform for strategic collaborations in oncology, cardiometabolic, pulmonary, and neurological diseases. Read the pre-print: biorxiv.org/content/10.110… Read the press release: mursla.com/mursla-bio-int… For partnering enquiries, contact us at: contact@mursla.com #PrecisionMedicine #ArtificialIntelligence #LiquidBiopsy #Diagnostics #EVScience #Biomarkers #MurslaBio #TissueSpecific #MultiOmics #NonInvasive

Last week our FDA Breakthrough Device Designation announcement was the most-read article on @GenomeWeb and @360DxNews – two of the most respected publications in the genomics and diagnostics space. This recognition reflects the growing momentum around our mission to change the way we detect liver cancer and improve patient outcomes. Our CEO, Pierre Arsène spoke to the editors about what this FDA milestone means for Mursla Bio, how we are using organ-specific EVs and multi-omics to shape the future of diagnostics and why our novel blood test EvoLiverTM could transform liver cancer surveillance for high risk individuals. A big thank you to GenomeWeb and 360Dx for spotlighting our work – and to everyone who’s been following our journey. Read the full articles here (paywall): genomeweb.com/cancer/mursla-… 360dx.com/cancer/mursla-… #FDA #BreakthroughDeviceDesignation #LiverCancer #Diagnostics #GenomeWeb #360Dx #MurslaBio

HCC Surveillance 2.0: FDA Recognizes @Mursla’s Extracellular Vesicle Test EvoLiver's @US_FDA Breakthrough Device designation could swing liver #cancer surveillance tests from ultrasound to blood-based. hubs.li/Q03jWGXS0

We are proud to announce that EvoLiver™, Mursla Bio’s flagship test for liver cancer surveillance, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The FDA awards Breakthrough Device Designation to a select number of medical devices that offer a more effective diagnosis of life-threatening diseases and represent a significant advancement over existing solutions. The Designation will support priority review, early feedback and more frequent FDA interactions to obtain FDA approved status for EvoLiver™, broadening its market reach and expediting commercial adoption. This follows the announcement of our latest clinical results at AASLD Liver Meeting in San Diego, CA in which EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies. We are currently progressing towards the launch of EvoLiver™ as a Laboratory Developed Test (LDT), while also advancing our plans for FDA approval via the PMA pathway, which will enable broader clinical adoption and scale-up. Check out our press release here: mursla.com/mursla-fda-rec… #FDA #BreakthroughDeviceDesignation #MurslaBio #EvoLiver #Diagnostics #EVscience #DynamicBiopsy #LiquidBiopsy

We are delighted to welcome Dr Raquel Sanches-Kuiper as Head of Research & Development at Mursla Bio. Raquel brings over 20 years of leadership experience in diagnostics, genomics and assay development, having most recently served as VP Science & Applications at Evonetix. There, she led multi-disciplinary teams across science and engineering, co-invented multiple patents, and played a key role in securing Series A and B funding. Earlier in her career at Solexa (later acquired by Illumina), Raquel helped establish the core molecular biology function and co-invented DNA polymerase technologies that were foundational to the company’s next-generation sequencing platform. Raquel’s expertise in frontier omics research, technology transfer and commercial readiness will be instrumental as we advance towards the scale-up of our Dynamic Biopsy platform to support the clinical implementation of our flagship product, EvoLiverTM as well as developing our product pipeline. Her arrival marks another important step in our journey to transform clinical diagnostics through organ-specific extracellular vesicles. #MurslaBio #ExtracellularVesicles #EVScience #Innovation #MultiOmics #DynamicBiopsy #LiquidBiopsy

🎉 We are thrilled to share that Mursla Bio has been shortlisted for TWO awards at the 2025 Cambridge Independent (@CambridgeIndy) Science and Technology Awards – The Award for Innovation and MedTech Company of the Year! Being recognised in Cambridge—one of the most vibrant and competitive biotech ecosystems in Europe and globally—is especially meaningful, and sets us on the right path globally as we prepare for our next phase of growth. This recognition is a fantastic endorsement of our vision to transform liver cancer surveillance through EvoLiver™, our Dynamic Biopsy-based blood test powered by organ-specific hepatocyte extracellular vesicles. Check out the full list of finalists: cambridgeindependent.co.uk/business/final… #MurslaBio #CambridgeIndependent #ExtracellularVesicles #EVScience #MedTech #Innovation #LiquidBiopsy

BioCentury's latest Emerging Company Profile features @Mursla, which is using extracellular vesicles to detect cancer. Led by ex-banker Pierre Arsène, the company's first goal is surveillance of cirrhosis patients at risk of liver cancer buff.ly/3PDLQ78

𝐓𝐡𝐞 𝐋𝐢𝐯𝐞𝐫 𝐌𝐞𝐞𝐭𝐢𝐧𝐠: @Mursla presented data suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity. #TLM24 Full video: biotechtv.com/post/mursla-bi…

🚨 EvoLiver™: Setting a New Standard in Liver Cancer Surveillance 🚨 At the AASLD Liver Meeting 2024, we unveiled exciting results from our multi-centre MEV01 study. EvoLiver™, our dynamic biopsy-based blood test, achieved 86% early-stage sensitivity and 88% specificity, surpassing current techniques like ultrasound and AFP. By isolating organ-specific hepatocyte extracellular vesicles (h-EVs) and analysing a novel multi-omics biomarker signature, EvoLiver™ provides precise, non-invasive detection of hepatocellular carcinoma (HCC) among high-risk cirrhotic patients. This scalable test addresses the growing need for earlier, more reliable liver cancer detection, transforming surveillance outcomes while enhancing patient adherence. We are proud to lead this paradigm shift in liver cancer care and thank our academic collaborators and team for their efforts. Next steps include publishing results in 2025, US LDT rollout, and securing FDA approval. More details here: mursla.com Together, we are redefining cancer surveillance. 🌎 #Innovation #DynamicBiopsy #LiverCancer #AASLD2024 #TLMdX

Our Founder & CEO Pierre Arsène spoke with the influential lifescience trade publication The Medicine Maker as part of the prediction’s series, “The Multifaceted Future of Pharma”. For the second piece in the series, Pierre discusses the upcoming clinical translation of extracellular vesicle (EV) science into highly innovative products that could benefit millions of patients in the future. Pierre comments: “Looking ahead, as technological innovations converge, EVs are well positioned to become one of the key biotech disruptors in the next 10 years.” Read the article: shorturl.at/AToK3 (free subscription required to access it)

October is Liver Cancer Awareness Month – a time when we come together to raise awareness and take action against one of the fastest-growing causes of cancer-related deaths. At Mursla Bio, this mission is deeply personal to us. We are committed to transforming liver cancer surveillance by enabling early detection, when it’s most treatable, as well as better accessibility. In support of this cause, the American Liver Foundation (@liverUSA) and Global Liver Institute (@GlobalLiver) have put together some valuable resources to spread awareness and promote liver health. Together, we can make a difference. #LiverCancerAwareness #LiverCancer #Octoberis4Livers #EarlyDetection #MurslaBio

🚀 Mursla Bio Expands to the US with New Office in Cambridge, MA! 🚀 We are thrilled to announce our expansion into the US market with a new office in Cambridge, Massachusetts! This marks a major step in transforming cancer diagnosis and treatment through our novel liquid biopsy tests based on extracellular vesicle (EV) technology. The new office, located in the dynamic biotech ecosystem of the Boston area will enhance Mursla Bio's ability to innovate and collaborate within the liquid biopsy field. This strategic positioning is pivotal for advancing the company's US Product Launch Plan and brings it closer to its customers globally. Please find more details in the link below 🔗 lnkd.in/eK_s7wXb hashtag#MurslaBio hashtag#LiquidBiopsy hashtag#CancerDiagnosis hashtag#BiotechInnovation hashtag#USExpansion hashtag#HealthcareTransformation hashtag#EVTechnology